KRAS and juvenile myelomonocytic leukemia: Although PTPN11, NRAS, KRAS, CBL, and NF1 mutations account for approximately 90% of JMML cases, around 10% of the patients that are clinically diagnosed with JMML do not present mutations in any of these five RAS pathway genes [37].